Impact of the CYP4F2 gene polymorphisms on the warfarin maintenance dose: A systematic review and meta-analysis

Sun,Xue; Yu,Wan‑Ying; Ma,Wan‑Le; Huang,Li‑Hua; Yang,Guo‑Ping

doi:10.3892/br.2016.599

Impact of the CYP4F2 gene polymorphisms on the warfarin maintenance dose: A systematic review and meta-analysis

Authors:
- Xue Sun
- Wan‑Ying Yu
- Wan‑Le Ma
- Li‑Hua Huang
- Guo‑Ping Yang
View Affiliations

Affiliations: Center of Clinical Pharmacology, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013, P.R. China, Center for Medical Experiments, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013, P.R. China
Published online on: February 15, 2016 https://doi.org/10.3892/br.2016.599
Pages: 498-506

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Warfarin is an oral anticoagulant with significant interpatient variability in dosage. A large number of studies have confirmed that the individual warfarin dose is mainly affected by the cytochrome P450 complex subunit 2C9 and vitamin K epoxide reductase complex subunit 1. However, the association between cytochrome P450 4F2 (CYP4F2) gene polymorphisms and warfarin dosage in the Asian population remains controversial. To investigate the impact of the CYP4F2 polymorphism rs2108622 (p.V433M) on warfarin dose requirement, a systematic review and meta‑analysis were conducted. According to the strict inclusion and exclusion criteria set, a comprehensive literature search was performed, and the studies published before August 5, 2015 were searched for in PubMed, EMBASE and the China National Knowledge Infrastructure databases. The references were checked by two independent reviewers. The association between the warfarin maintenance dose and CYP4F2 polymorphism was analyzed. Twenty‑two studies were included in the meta‑analysis. Compared with the CYP4F2 genotype CC, carriers of the CT and TT genotypes required a 9 [95% confidence interval (CI): 6.0‑13.0] and 20% (95% CI, 13.0‑27.0) higher warfarin dose, respectively. In the combined analysis, T carriers (CT+TT) required an 11% (95% CI, 8.0‑14.0) higher warfarin dose compared to the CC genotype. In addition, there was a 10% (95% CI, 5.0‑15.0) higher warfarin dose in TT carriers compared to the CT genotype (all P<0.05). The results of the meta‑analysis suggest that the effects of the CYP4F2 polymorphism on individual warfarin dose have a statistically significant difference, and the effect degree is variable in the subgroups. Further studies are expected to explore whether the pharmacogenetics model including the CYP4F2 polymorphism can strengthen the prediction of warfarin dose.

View Figures

View References

1	Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, et al: International Warfarin Pharmacogenetics Consortium: Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 360:753–764. 2009. View Article : Google Scholar : PubMed/NCBI
2	Zhu Y, Shennan M, Reynolds KK, Johnson NA, Herrnberger MR, Valdes R Jr and Linder MW: Estimation of warfarin maintenance dose based on VKORC1 (−1639 G>A) and CYP2C9 genotypes. Clin Chem. 53:1199–1205. 2007. View Article : Google Scholar : PubMed/NCBI
3	Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, Milligan PE, Grice G, Lenzini P, Rettie AE, et al: Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 84:326–331. 2008. View Article : Google Scholar : PubMed/NCBI
4	Ohno M, Yamamoto A, Ono A, Miura G, Funamoto M, Takemoto Y, Otsu K, Kouno Y, Tanabe T, Masunaga Y, et al: Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients. Eur J Clin Pharmacol. 65:1097–1103. 2009. View Article : Google Scholar : PubMed/NCBI
5	Cini M, Legnani C, Cosmi B, Guazzaloca G, Valdrè L, Frascaro M and Palareti G: A new warfarin dosing algorithm including VKORC1 3730 G>A polymorphism: Comparison with results obtained by other published algorithms. Eur J Clin Pharmacol. 68:1167–1174. 2012. View Article : Google Scholar : PubMed/NCBI
6	Huang SW, Chen HS, Wang XQ, Huang L, Xu DL, Hu XJ, Huang ZH, He Y, Chen KM, Xiang DK, et al: Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: A prospective study in Chinese patients. Pharmacogenet Genomics. 19:226–234. 2009. View Article : Google Scholar : PubMed/NCBI
7	Teichert M, Eijgelsheim M, Rivadeneira F, Uitterlinden AG, van Schaik RH, Hofman A, De Smet PA, van Gelder T, Visser LE and Stricker BH: A genome-wide association study of acenocoumarol maintenance dosage. Hum Mol Genet. 18:3758–3768. 2009. View Article : Google Scholar : PubMed/NCBI
8	McDonald MG, Rieder MJ, Nakano M, Hsia CK and Rettie AE: CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant. Mol Pharmacol. 75:1337–1346. 2009. View Article : Google Scholar : PubMed/NCBI
9	Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P, Hubbard J, Turpaz Y, Langaee TY, Eby C, et al: CYP4F2 genetic variant alters required warfarin dose. Blood. 111:4106–4112. 2008. View Article : Google Scholar : PubMed/NCBI
10	Lee MT, Chen CH, Chou CH, Lu LS, Chuang HP, Chen YT, Saleem AN, Wen MS, Chen JJ, Wu JY, et al: Genetic determinants of warfarin dosing in the Han-Chinese population. Pharmacogenomics. 10:1905–1913. 2009. View Article : Google Scholar : PubMed/NCBI
11	Liang R, Li L, Li C, Gao Y, Liu W, Hu D and Sun Y: Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients. J Thromb Thrombolysis. 34:120–125. 2012. View Article : Google Scholar : PubMed/NCBI
12	Li JH, Ma GG, Zhu SQ, Yan H, Wu YB and Xu JJ: Correlation between single nucleotide polymorphisms in CYP4F2 and warfarin dosing in Chinese valve replacement patients. J Cardiothorac Surg. 7:972012. View Article : Google Scholar : PubMed/NCBI
13	Liang Y, Chen Z, Guo G, Dong X, Wu C, Li H, Wang T and Xu B: Association of genetic polymorphisms with warfarin dose requirements in Chinese patients. Genet Test Mol Biomarkers. 17:932–936. 2013. View Article : Google Scholar : PubMed/NCBI
14	Li S, Zou Y, Wang X, Huang X, Sun Y, Wang Y, Dong L and Jiang H: Warfarin dosage response related pharmacogenetics in Chinese population. PLoS One. 10:e01164632015. View Article : Google Scholar : PubMed/NCBI
15	Zhuang W, Wen W, Xuan B, Chen Y, Cao Y, Sun Z and Ma J: Effect of CYP2C9, CYP4F2 and VKORC1 genetic polymorphisms on pharmacokinetics and pharmacodynamics of mean daily maintenance dose of warfarin in Chinese patients. Blood Coagul Fibrinolysis. 26:167–174. 2015. View Article : Google Scholar : PubMed/NCBI
16	Danese E, Montagnana M, Johnson JA, Rettie AE, Zambon CF, Lubitz SA, Suarez-Kurtz G, Cavallari LH, Zhao L, Huang M, et al: Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: Systematic review and meta-analysis. Clin Pharmacol Ther. 92:746–756. 2012. View Article : Google Scholar : PubMed/NCBI
17	Liang R, Wang C, Zhao H, Huang J, Hu D and Sun Y: Influence of CYP4F2 genotype on warfarin dose requirement-a systematic review and meta-analysis. Thromb Res. 130:38–44. 2012. View Article : Google Scholar : PubMed/NCBI
18	Little J, Bradley L, Bray MS, Clyne M, Dorman J, Ellsworth DL, Hanson J, Khoury M, Lau J, O'Brien TR, et al: Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. Am J Epidemiol. 156:300–310. 2002. View Article : Google Scholar : PubMed/NCBI
19	Lindh JD, Holm L, Andersson ML and Rane A: Influence of CYP2C9 genotype on warfarin dose requirements - a systematic review and meta-analysis. Eur J Clin Pharmacol. 65:365–375. 2009. View Article : Google Scholar : PubMed/NCBI
20	Cen HJ, Zeng WT, Leng XY, Huang M, Chen X, Li JL, Huang ZY, Bi HC, Wang XD, He YL, et al: CYP4F2 rs2108622: A minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement. Br J Clin Pharmacol. 70:234–240. 2010. View Article : Google Scholar : PubMed/NCBI
21	Lou Y, Han L and Li Y, Zhang X, Liu Z, Tang M, Yu H, Wang W, Xu J, Liu H and Li Y: Impact of six genetic polymorphisms on Warfarin maintenance dose variation in Chinese Han population. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 31:367–371. 2014.(In Chinese). PubMed/NCBI
22	Zhang HY, Luo WW, Fang HR, Yang XQ, Xu LH and Ma SM: Influence of VKORC1, CYP2C9, CYP4F2 and EPHX1 Gene Polymorphisms on Warfarin Dose. China Pharmacy. 34:3201–3205. 2012.
23	Zhu JR, Zhu YB, Xie DJ, Ye F and Tao YF: Effects of CYP4F2, CYP2C9 and VKORC1 genetic polymorphisms on maintenance dosage of warfarin in Chinese Han nationality patients with non-valve atrial fibrillation. China Pharmacy. 44:4161–4164. 2012.
24	Wang Z, Yang D, Li YL, et al: Influence of CYP4F2 gene polymorphisms on warfarin dose. Guangdong Medical Journal. 3091–3094. 2011.
25	Zhang YT, Liang X, Dong F, et al: Effect of CYP4F2 polymorphism on warfarin anticoagulant in Chinese population. Clinical Medication Journal. 41–59. 2014.
26	Krishna Kumar D, Shewade DG, Loriot MA, Beaune P, Balachander J, Sai Chandran BV and Adithan C: Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population. Eur J Clin Pharmacol. 70:47–56. 2014. View Article : Google Scholar : PubMed/NCBI
27	Özer M, Demirci Y, Hizel C, Sarikaya S, Karalti İ, Kaspar Ç, Alpan S and Genç E: Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population. Basic Clin Pharmacol Toxicol. 112:209–214. 2013. View Article : Google Scholar : PubMed/NCBI
28	Hirai K, Yamada Y, Hayashi H, Tanaka M, Izumiya K, Suzuki M, Yoshizawa M, Moriwaki H, Akimoto T, Tsuji D, et al: Plasma vitamin K concentrations depend on CYP4F2 polymorphism and influence on anticoagulation in Japanese patients with warfarin therapy. Thromb Res. 135:861–866. 2015. View Article : Google Scholar : PubMed/NCBI
29	Nakamura K, Obayashi K, Araki T, Aomori T, Fujita Y, Okada Y, Kurabayashi M, Hasegawa A, Ohmori S, Nakamura T, et al: CYP4F2 gene polymorphism as a contributor to warfarin maintenance dose in Japanese subjects. J Clin Pharm Ther. 37:481–485. 2012. View Article : Google Scholar : PubMed/NCBI
30	Lee KE, Chang BC, Kim HO, Yoon IK, Lee NR, Park HY and Gwak HS: Effects of CYP4F2 gene polymorphisms on warfarin clearance and sensitivity in Korean patients with mechanical cardiac valves. Ther Drug Monit. 34:275–282. 2012. View Article : Google Scholar : PubMed/NCBI
31	Singh O, Sandanaraj E, Subramanian K, Lee LH and Chowbay B: Influence of CYP4F2 rs2108622 (V433M) on warfarin dose requirement in Asian patients. Drug Metab Pharmacokinet. 26:130–136. 2011. View Article : Google Scholar : PubMed/NCBI
32	Jorgensen AL, FitzGerald RJ, Oyee J, Pirmohamed M and Williamson PR: Influence of CYP2C9 and VKORC1 on patient response to warfarin: A systematic review and meta-analysis. PLoS One. 7:e440642012. View Article : Google Scholar : PubMed/NCBI
33	Yang L, Ge W, Yu F and Zhu H: Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement - a systematic review and meta analysis. Thromb Res. 125:e159–e166. 2010. View Article : Google Scholar : PubMed/NCBI
34	Jin B, Hong Y, Zhu J, Li Y and Shi HM: The impact of VKORC1-1639G>A genetic polymorphism upon warfarin dose requirement in different ethnic populations. Curr Med Res Opin. 30:1505–1511. 2014. View Article : Google Scholar : PubMed/NCBI
35	Limdi NA, Brown TM, Yan Q, Thigpen JL, Shendre A, Liu N, Hill CE, Arnett DK and Beasley TM: Race influences warfarin dose changes associated with genetic factors. Blood. 126:539–545. 2015. View Article : Google Scholar : PubMed/NCBI